Drug Information Update - New FDA Drug Info: Drug Safety Podcasts

FDA's Division of Drug Information has posted new Drug Safety Podcasts for Healthcare Professionals. Click on the following links to read transcripts and listen to podcasts.

•   FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use
•   FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking
•   FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)
•   FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another Direct Acting Antiviral drug

You can download other Drug Safety Podcasts at: FDA Drug Safety Podcasts or subscribe to the Drug Safety Podcasts channel in iTunes at: Drug Safety Podcasts.

---

This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.

• For additional drug information, please visit the DDI Web page.
• For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.
• This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).